Polymers specifically designed to degrade under physiological conditions are often referred to as ‘absorbable’, ‘biodegradable’ or ‘bioresorbable’ polymers.
With this in-licensing event, the Polymer Technology Group (PTG) will now be able to offer a wider range of new and generic bioresorbable polymers to the medtech industry for use in medical devices, drug delivery and tissue engineering.
Bob Ward, CEO of PTG, said: “We are very happy to be working with Dr Bezwada, who has more than 25 years of research experience in the medical device industry, including 20 years of service at Ethicon (Johnson & Johnson) prior to establishing Bezwada Biomedical in 2003.”